RSS

SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021

October 6, 2021
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

October 4, 2021
SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

September 28, 2021
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19

SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19

September 24, 2021
Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics

Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics

September 23, 2021
SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza

SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza

September 15, 2021

Cows Help With COVID-19 Treatment, No Bull

June 17, 2020
Human Trials Expected To Start Next Month For Covid-19 Treatment Derived From Cows’ Blood

Human Trials Expected To Start Next Month For Covid-19 Treatment Derived From Cows’ Blood

June 16, 2020
This Cow’s Antibodies Could Be The Newest Weapon Against COVID-19

This Cow’s Antibodies Could Be The Newest Weapon Against COVID-19

June 5, 2020
Researchers Use Cows To Develop Antibody Treatment

Researchers Use Cows To Develop Antibody Treatment

May 20, 2020
I Am BIO | “Herd” Immunity Podcast

I Am BIO | “Herd” Immunity Podcast

May 7, 2020